کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5623213 1406201 2013 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Featured ArticleBenefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease
ترجمه فارسی عنوان
مزایای ویژه ای از مهارکننده ترکیبی کولین استراز و درمان ممتینین در بیماری آلزایمر متوسط ​​و شدید
کلمات کلیدی
ترکیبی مواد مخدر، آلزایمر، رفتار،
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی عصب شناسی
چکیده انگلیسی

BackgroundClinical studies and post hoc analyses have investigated the use of combination therapy for the treatment of Alzheimer's disease (AD). We review the evidence for the short- and long-term efficacy of combination therapy in AD.MethodsThe review is based on a search of the PubMed database to identify relevant articles concerning combination treatment with memantine and cholinesterase inhibitors (ChEIs).ResultsIn patients with moderate-to-severe AD, combination treatment with the N-methyl-d-aspartate receptor antagonist memantine and the ChEI donepezil has produced significant benefits in cognition, function, behavior, global outcome, and care dependency, compared with donepezil treatment alone. Data from long-term observational studies support these findings. Compared with ChEI monotherapy, combination treatment slowed cognitive and functional decline (a 4-year sustained effect that appeared to increase over time) and reduced the risk of nursing home admission. Preclinically, the combination of N-methyl-d-aspartate receptor modulation and acetylcholinesterase inhibition has been shown to act synergistically, which may explain the observed clinical effects of combination treatment.ConclusionTreatment with memantine/ChEI combination therapy in moderate-to-severe AD produces consistent benefits that appear to increase over time, and that are beyond those of ChEI treatment alone.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Alzheimer's & Dementia - Volume 9, Issue 3, May 2013, Pages 326-331
نویسندگان
, ,